| ADULT MEDICATION GUIDELINE | |
|---|---|
| # Midazolam | |
| **Scope (Staff):** | All WNHS Staff |
| **Scope (Area):** | Obstetrics and Gynaecology |
| **This document should be read in conjunction with the Disclaimer.** | |

## Quick Links

| | | | |
|---|---|---|---|
| Dose | Administration | Monitoring | Pregnancy and Breastfeeding |

## Restrictions

**Formulary: Unrestricted**

HIGH RISK Medication

## Medication Class

Benzodiazepine (short acting)

## Presentation

**Ampoule:** 5mg/5mL, 5mg/mL

## Storage

**Ampoule:** Store at room temperature, below 25°C

**Schedule 4 Restricted Medication**

## Dose

**Conscious sedation:**

**IV:**

2 to 2.5 mg followed by 1 mg doses after 3-minute intervals if required. Maximum of 5 mg.

If elderly or debilitated, use 1 to 1.5 mg initially.

**Refractory PONV despite multiple antiemetic interventions:**

**IV:**

If nausea persists; infuse 1mg/hour for 24 hours.

(Must be discussed with the duty Anaesthetist prior to use)

**Eclampsia / status epilepticus:**

**IV/IM:**

0.1 to 0.2 mg/kg (5 to 10 mg).

**Induction of anaesthesia:**

**IV:**

0.15 to 0.2 mg/kg administered at a rate of approximately 2.5 mg per 10 seconds

**Local anaesthetic toxicity:**

**IV:**

2.5 to 5 mg stat (to terminate convulsions).

## Administration

Refer to the Australian Injectable Drugs Handbook

## Monitoring

Requires ANZCA standard monitoring (HR, BP, SpO2) during infusion and post administration.

Respiratory depression, cardiovascular system depression, apnoea, impaired conscious state, muscle tremor, involuntary movements, slurred speech, anterograde amnesia.

## Pregnancy

**1st Trimester:** Considered safe to use

**2nd Trimester:** Considered safe to use

**3rd Trimester:** Considered safe to use

For more information, please contact KEMH Obstetric Medicines Information Service.

## Breastfeeding

Considered safe to use

For more information, please contact KEMH Obstetric Medicines Information Service.

## Comments

Onset of clinical effect may be delayed; there is a danger of overdosage if midazolam is given rapidly without waiting to assess its effects.

## Related Policies, Procedures & Guidelines

**HDWA Mandatory Policies:**

Medicines Handling Policy

**WNHS Clinical Practice Guidelines:**

Anaesthesia and Pain Medicine Protocol: Adult resuscitation drug protocols

Anaesthesia and Pain Medicine Clinical Practice Guideline: Neuraxial analgesia (including epidura intrathecal morphine)

Anaesthesia and Pain Medicine Clinical Practice Guideline: Lidocaine (lignocaine) infusion: Intravenous

Hypertension in pregnancy: Medical management

**WNHS Pharmaceutical and Medicines Management Guidelines:**

High Risk Medicines

Medication Administration

Schedule 4 Restricted (S4R) and Schedule 8 (S8) Medications

## References

Australian Medicines Handbook. Midazolam. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2025 [cited Feb 20]. Available from: https://amhonline.amh.net.au/

Therapeutic Guidelines. Neurology: Acute management of seizures and status epilepticus. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2025 March 03]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

Therapeutic Guidelines. Pain and Analgesia: Procedural sedation and analgesia. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2025 March 03]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Midazolam. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2025 Feb 20]. Available from: https://thewomenspbmg.org.au/

Di Florio T, Goucke CR. The effect of midazolam on persistent postoperative nausea and vomiting. Anaesth Intensive Care. 1999;27(1):38-40. doi:10.1177/0310057X9902700107

| | | | | | |
|---|---|---|---|---|---|
| Keywords | Midazolam, anaesthesia, sedation, seizure, epidural, nausea | | | | |
| Document Owner: | Chief Pharmacist | | | | |
| Author/ Reviewer | KEMH Pharmacy Department | | | | |
| Version Info: | 6.0 | | | | |
| Date First Issued: | 07/2015 | Last Reviewed: | May 2025 | Review Date: | May 2030 |
| Endorsed by: | Medicines and Therapeutics Committee | | | Date: | 03/06/2025 |
| NSQHS Standards Applicable: | ☒ Std 1: Clinical Governance<br>☐ Std 2: Partnering with Consumers<br>☐ Std 3: Preventing and Controlling Healthcare Associated Infection<br>☒ Std 4: Medication Safety | | | ☐ Std 5: Comprehensive Care<br>☐ Std 6: Communicating for Safety<br>☐ Std 7: Blood Management<br>☐ Std 8: Recognising and Responding to Acute Deterioration | |
| **Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.** | | | | | |

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2025

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.